Segment Information (Tables)

6 Months Ended

Jun. 30, 2014

	Three Months Ended June 30, 2014 ($000)										Three Months Ended June 30, 2013 ($000)
	Bio-			ProElite							Bio-		ProElite
	Pharma			(Discont.)		Other		Total			Pharma		(Discont.)			Other			Total
Revenues	$	—		$	—	$	—	$	—		$	—	$			$	—		$	—
Cost of sales	—			—		—		—			—		—			—			—
Gross margin	—			—		—		—			—					—			—
Depreciation and amortization	610			—		—		610			—					7			7
Segment profit	(610		)	—		—		(610		)	—		—			(7		)	(7		)
Operating expenses	3,897			—		—		3,897			—		—			8,090			8,090
Other (income)/expenses	(52		)	—		—		(52		)	—					(1,356		)	(1,356		)
Impact of derivative securities	—			—		—		—			—		—			(9,217		)	(9,217		)
Net income (loss) from continuing ops.	(4,455		)	—		—		(4,455		)	—					2,476			2,476
Loss from discontinued ops.	—			—		—		—			—		(129		)	—			(129		)
Preferred dividends	—			—		—		—			—		—			47			47
Net income (loss) attributable to common shareholders	$	(4,455	)	$	—	$	—	$	(4,455	)	$	—	$	(129	)	$	2,429		$	2,300

	Six Months Ended June 30, 2014 ($000)										Six Months Ended June 30, 2013 ($000)
	Bio-			ProElite							Bio-		ProElite
	Pharma			(Discont.)		Other		Total			Pharma		(Discont.)			Other			Total
Revenues	$	—		$	—	$	—	$	—		$	—	$			$	—		$	—
Cost of sales	—			—		—		—			—		—			—			—
Gross margin	—			—		—		—			—					—			—
Depreciation and amortization	1,089			—		—		1,089			—					17			17
Segment profit	(1,089		)	—		—		(1,089		)	—		—			(17		)	(17		)
Operating expenses	4,790			—		—		4,790			—		—			10,139			10,139
Other (income)/expenses	(44		)	—		—		(44		)	—					107			107
Impact of derivative securities	—			—		—		—			—		—			(10,390		)	(10,390		)
Net income (loss) from continuing ops.	(5,835		)	—		—		(5,835		)	—					(127		)	(127		)
Loss from discontinued ops.	—			—		—		—			—		(256		)	—			(256		)
Preferred dividends	—			—		—		—			—		—			172			172
Net loss attributable to common shareholders	$	(5,835	)	$	—	$	—	$	(5,835	)	$	—	$	(256	)	$	(45	)	$	(301	)

Assets at end of period	$	54,529		$	—	$	—	$	54,529		$	—	$	26		$	172		$	197
Liabilities at end of period	$	9,170		$	62	$	—	$	9,232		$	—	$	1,517		$	7,250		$	8,767

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details